Health-Related Quality of Life Across the Spectrum of Pulmonary Hypertension.

health-related quality of life pulmonary hypertension

Journal

Chest
ISSN: 1931-3543
Titre abrégé: Chest
Pays: United States
ID NLM: 0231335

Informations de publication

Date de publication:
12 Feb 2024
Historique:
received: 23 07 2023
revised: 05 01 2024
accepted: 08 02 2024
medline: 15 2 2024
pubmed: 15 2 2024
entrez: 14 2 2024
Statut: aheadofprint

Résumé

Health related quality of life (HRQOL) is frequently impaired in pulmonary arterial hypertension (PAH). However, little is known about HRQOL in other forms of pulmonary hypertension (PH). Does HRQOL vary across groups of the World Symposium on Pulmonary Hypertension (WSPH) classification system? This cross-sectional study included PH patients from PVDOMICS (Pulmonary Vascular Disease Phenomics). HRQOL was assessed using emPHasis-10 (e-10), Medical Outcomes Survey Short Form-36 (SF-36; physical component (PCS) and mental component (MCS)), and Minnesota Living with Heart Failure Questionnaire (MLHF). Pearson's correlations between HRQOL and demographic, physiologic, and imaging characteristics within each WSPH group were tested. Multivariable linear regressions compared HRQOL across WSPH groups adjusting for demographics, disease prevalence, functional class, and hemodynamics. Cox proportional hazard models were used to assess associations between HRQOL and survival across WSPH groups. Among 691 PH patients, HRQOL correlated with functional class and six-minute walk distance but not hemodynamics. HRQOL was severely depressed across WSPH groups for all measures except the SF-36 MCS. When compared to Group 1, Group 2 subjects had significantly worse HRQOL (e-10: 29 vs 24, p=0.001, PCS: 32.9 ± 8 vs 38.4 ± 10, p<0.0001, MLHF: 50 vs 38, p=0.003). Group 3 subjects similarly had worse e-10 (31 vs 24, p<0.0001) and PCS scores (33.3 ± 9 vs 38.4 ± 10, p<0.0001) compared to Group 1, which persisted in multivariable models (p<0.05). HRQOL was associated in adjusted models with survival across Groups 1, 2, and 3. HRQOL is depressed in PH and particularly in Groups 2 and 3 despite less severe hemodynamics. HRQOL is associated with functional capacity, but hemodynamic disease severity poorly estimates the impact of PH on patient's lives. Further studies are needed to better identify predictors and treatments to improve HRQOL across the spectrum of pulmonary hypertension.

Sections du résumé

BACKGROUND BACKGROUND
Health related quality of life (HRQOL) is frequently impaired in pulmonary arterial hypertension (PAH). However, little is known about HRQOL in other forms of pulmonary hypertension (PH).
RESEARCH QUESTION OBJECTIVE
Does HRQOL vary across groups of the World Symposium on Pulmonary Hypertension (WSPH) classification system?
STUDY DESIGN AND METHODS METHODS
This cross-sectional study included PH patients from PVDOMICS (Pulmonary Vascular Disease Phenomics). HRQOL was assessed using emPHasis-10 (e-10), Medical Outcomes Survey Short Form-36 (SF-36; physical component (PCS) and mental component (MCS)), and Minnesota Living with Heart Failure Questionnaire (MLHF). Pearson's correlations between HRQOL and demographic, physiologic, and imaging characteristics within each WSPH group were tested. Multivariable linear regressions compared HRQOL across WSPH groups adjusting for demographics, disease prevalence, functional class, and hemodynamics. Cox proportional hazard models were used to assess associations between HRQOL and survival across WSPH groups.
RESULTS RESULTS
Among 691 PH patients, HRQOL correlated with functional class and six-minute walk distance but not hemodynamics. HRQOL was severely depressed across WSPH groups for all measures except the SF-36 MCS. When compared to Group 1, Group 2 subjects had significantly worse HRQOL (e-10: 29 vs 24, p=0.001, PCS: 32.9 ± 8 vs 38.4 ± 10, p<0.0001, MLHF: 50 vs 38, p=0.003). Group 3 subjects similarly had worse e-10 (31 vs 24, p<0.0001) and PCS scores (33.3 ± 9 vs 38.4 ± 10, p<0.0001) compared to Group 1, which persisted in multivariable models (p<0.05). HRQOL was associated in adjusted models with survival across Groups 1, 2, and 3.
INTERPRETATION CONCLUSIONS
HRQOL is depressed in PH and particularly in Groups 2 and 3 despite less severe hemodynamics. HRQOL is associated with functional capacity, but hemodynamic disease severity poorly estimates the impact of PH on patient's lives. Further studies are needed to better identify predictors and treatments to improve HRQOL across the spectrum of pulmonary hypertension.

Identifiants

pubmed: 38354903
pii: S0012-3692(24)00155-7
doi: 10.1016/j.chest.2024.02.009
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Auteurs

Aparna Balasubramanian (A)

Division of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, MD.

Brett Larive (B)

Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH.

Evelyn M Horn (EM)

Division of Cardiology, Weill Cornell Medicine, New York, NY.

Hilary M DuBrock (HM)

Department of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota.

Reena Mehra (R)

Neurologic and Respiratory Institutes, Cleveland Clinic, Cleveland, Ohio.

Miriam Jacob (M)

Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio.

Anna R Hemnes (AR)

Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN.

Jane A Leopold (JA)

Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Milena K Radeva (MK)

Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH.

Nicholas S Hill (NS)

Division of Pulmonary, Critical Care, and Sleep Medicine, Tufts Medical Center, Boston, Massachusetts.

Serpil C Erzurum (SC)

Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.

Erika Berman-Rosenzweig (E)

Department of Pediatrics and Medicine, Columbia University, New York, New York.

Robert Frantz (R)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.

Franz P Rischard (FP)

Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Arizona, Tucson, Arizona.

Gerald Beck (G)

Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH.

Paul M Hassoun (PM)

Division of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, MD.

Stephen C Mathai (SC)

Division of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, MD. Electronic address: smathai4@jhmi.edu.

Classifications MeSH